The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma.
CD133 (Prominin-1) is considered the most important cancer stem cell (CSC)-associated marker identified so far, with increased expression in the CSC fraction of a large variety of human malignancies, including melanoma. Here we investigated the effects of CD133 downregulation in vitro and in vivo in human metastatic melanoma. The average number of CD133 molecules on the cell surface of FEMX-I melanoma cells was decreased by 8.7-fold and 1.8-fold using two different short hairpin RNAs. Downregulation of CD133, confirmed by immunocytochemistry, Western blotting, microarray analysis, and reverse transcription-polymerase chain reaction, resulted in slower cell growth, reduced cell motility, and decreased capacity to form spheroids under stem cell-like growth conditions. Clonal analysis revealed that the reduction in growth rate was proportional to the extent of CD133 downregulation. Monoclonal antibodies directed against two different epitopes of the CD133 protein induced a specific, dose-dependent cytotoxic effect in FEMX-I cells. The downregulation of CD133 severely reduced the capacity of the cells to metastasize, particularly to the spinal cord. In the CD133 downregulated cells, microarray analysis revealed expression changes for only 143 annotated genes (76 up- and 67 downregulated). Ten of the 76 upregulated genes coded for Wnt inhibitors, suggesting an interaction between CD133 and the canonical Wnt pathway. We conclude that CD133, in addition to its role as a CSC marker, is an important therapeutic target for metastatic melanoma and, potentially, for other CD133-expressing cancer types.
Rappa
Germana
G
Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama 36688, USA.
Fodstad
Oystein
O
Lorico
Aurelio
A
D000071916:AC133 Antigen; D015703:Antigens, CD / Q000096:biosynthesis*; D045744:Cell Line, Tumor; D002465:Cell Movement; D002469:Cell Separation; D015972:Gene Expression Regulation, Neoplastic; D006023:Glycoproteins / Q000096:biosynthesis*; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008545:Melanoma / Q000188:drug therapy / Q000378:metabolism*; D009362:Neoplasm Metastasis; D014411:Neoplastic Stem Cells / Q000378:metabolism*; D020411:Oligonucleotide Array Sequence Analysis; D010455:Peptides; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018874:Spheroids, Cellular / Q000378:metabolism; D014407:Tumor Cells, Cultured; D051153:Wnt Proteins / Q000378:metabolism
D000071916:AC133 Antigen; D015703:Antigens, CD; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides; D051153:Wnt Proteins
Cancer Res. 2003 Sep 15;63(18):5821-8
14522905
Nature. 2008 Jul 17;454(7202):345-9
18528331
Cancer Res. 1988 Aug 1;48(15):4382-8
3390834
Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12425-30
9356465
Blood. 1997 Dec 15;90(12):5002-12
9389720
Cancer Res. 1997 Dec 1;57(23):5238-42
9393741
Cancer Res. 2005 Oct 15;65(20):9328-37
16230395
Cancer Res. 2005 Dec 1;65(23):10946-51
16322242
Cancer Res. 2006 Aug 1;66(15):7445-52
16885340
Nature. 2006 Dec 7;444(7120):761-5
17151667
Nature. 2007 Jan 4;445(7123):111-5
17122771
Nature. 2007 Jan 4;445(7123):106-10
17122772
Eur J Cancer. 2007 Mar;43(5):935-46
17320377
Curr Opin Cell Biol. 2007 Apr;19(2):150-8
17306971
Int J Mol Med. 2007 Jun;19(6):967-70
17487431
Biochem J. 2008 Jan 1;409(1):53-64
17908054
Nature. 2008 Jan 17;451(7176):345-9
18202660
Cancer Res. 2008 Apr 15;68(8):2803-12
18413748
Exp Cell Res. 2008 Jun 10;314(10):2110-22
18423605
Br J Cancer. 2008 Jul 8;99(1):100-9
18542072
J Biol Chem. 2004 Apr 23;279(17):17535-42
14739301